The medication is an anti-cancer targeted therapy drug that belongs to a class of tyrosine kinase inhibitors (TKIs). It helps to stop the multiplication and rapid division of harmful cancer cells. The ponatinib tablet uses its effective mechanism to treat Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL).